NUS earnings analysis
What we found in NUS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Nu Skin’s Q2 revenue was $320.112 million, approximately 17.1% below the $386 million reported in Q2 2025 and 7.3% below consensus, while adjusted EPS of $0.20 matched expectations. GAAP EPS was negative $5.14 because of a $78.875 million impairment charge. Management lowered FY2026 revenue guidance to $1.28-$1.35 billion and adjusted EPS guidance to $0.70-$0.90, and the company drew $30 million on its revolver, bringing the balance to $70 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Fell 17.1% Year Over Year
- Q2 revenue was $320.112 million, down from $386 million in Q2 2025, a decrease of approximately 17.1%, and missed the $345.2 million consensus estimate by 7.3%.
- Adjusted EPS Met Consensus
- GAAP EPS was negative $5.14, primarily reflecting a $78.875 million impairment charge. Adjusted EPS was $0.20, matching the $0.20 consensus estimate.
- Revolver Draw Increased Liquidity Support
- The company drew $30 million under its revolving credit facility on August 6, 2026, bringing the total revolving-credit balance to $70 million as of the filing date.
- Planned $25 Million Debt Repayment
- Management anticipates repaying approximately $25 million during the third quarter of 2026, implying a potential reduction of the stated revolving-credit balance to approximately $45 million if completed.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large Impairment Depressed GAAP Earnings
- The $78.875 million impairment charge drove GAAP EPS to negative $5.14 in Q2, highlighting continued pressure on asset values and reported profitability.
- Lowered Full-Year Outlook
- FY2026 revenue guidance was reduced to $1.28-$1.35 billion from $1.35-$1.50 billion, while adjusted EPS guidance was reduced to $0.70-$0.90 from $0.70-$1.10.
- Higher Revolving-Credit Balance
- The company had $70 million outstanding under its revolving credit facility as of the filing date after a $30 million draw, creating added refinancing and liquidity exposure despite the anticipated $25 million Q3 repayment.
- Foreign-Exchange Exposure
- The filing states that a majority of revenue and many expenses are recognized outside the United States, and that a strengthening U.S. dollar negatively affects reported revenue and earnings. Argentina represented less than 4% of consolidated net sales for the six months ended June 30, 2026.
- No Material Risk-Factor Changes
- The filing reports no material changes from the risk factors disclosed in the 2025 Form 10-K; however, the company continues to describe potentially significant currency sensitivity because a large portion of its business is outside the United States.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-5.14
What they said about what is next.
FY2026 adjusted EPS guidance was lowered to $0.70-$0.90 from $0.70-$1.10; FY2026 revenue guidance was lowered to $1.28-$1.35 billion from $1.35-$1.50 billion. Q3 adjusted EPS guidance is $0.10-$0.20.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Nu Skin Enterprises reported Q1 2026 results showing a revenue decline of 12.0% year-over-year to $320.6 million, and a significant drop in EPS to $0.04 from $2.14 in the same period last year. The company's adjusted…
- 10-K · February 13, 2026
- Nu Skin Enterprises Inc. (NUS) experienced a significant decline in revenue and customer metrics in 2025 due to ongoing global macroeconomic challenges that continued to dampen consumer spending. Revenue dropped 14% to…
- 10-Q · November 7, 2025
- Nu Skin Enterprises, Inc. reported a challenging third quarter in 2025, with revenues of $364.2 million, down 15% from $430.1 million year-over-year. However, earnings per share increased to $0.34 due to lower expenses…
- 10-Q · August 8, 2025
- Nu Skin Enterprises, Inc. reported Q2 revenues of $386.1 million, a decline of 12% year-over-year, but better than analysts' expectations, with reported EPS of $0.43 compared to a loss of $2.38 in the prior year. While…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NUS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever